Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2019 01:00 ET | Source: Addex Therapeutics

Addex to Receive Additional $800K Funding from Indivior for GABAB PAM Addiction Program

Geneva, Switzerland, December 20, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that Indivior PLC (LON: INDV)...
December 18, 2019 01:00 ET | Source: Addex Therapeutics

ADDEX THERAPEUTICS PUBLICLY FILES REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSs REPRESENTING SHARES

Geneva, Switzerland, 18 December 2019 -- Addex Therapeutics Ltd (SIX: ADXN) (the Company), a leading company pioneering allosteric modulation-based drug discovery and development, today announced it...
December 03, 2019 01:00 ET | Source: Addex Therapeutics

Addex: Van Leeuwenhoeck Issues Update Equity Research Report

Geneva, Switzerland, December 3, 2019 – Addex Therapeutics (SIX: ADXN), a clinical-stage leading allosteric modulation-based drug discovery and development company, today announced the independent...
November 13, 2019 01:00 ET | Source: Addex Therapeutics

Addex to Attend Jefferies 2019 London Healthcare Conference

Geneva, Switzerland, November 13, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that Chief Executive Officer, Tim...
November 08, 2019 01:00 ET | Source: Addex Therapeutics

Addex to Attend BIO-Europe Conference in Hamburg

Geneva, Switzerland, November 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that Chief Executive Officer Tim...
October 08, 2019 01:00 ET | Source: Addex Therapeutics

Addex to Receive Additional Funding from Indivior for GABAB PAM Addiction Program

Indivior Investment Reflects Progress Towards Clinical Evaluation and Validates Power of Allosteric Platform Geneva, Switzerland, October 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading...
September 30, 2019 01:00 ET | Source: Addex Therapeutics

Addex Reports 2019 Half-Year Financial Results and Provides Corporate Update

Geneva, Switzerland, September 30, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today reported its half-year financial results...
September 25, 2019 01:00 ET | Source: Addex Therapeutics

ADDEX THERAPEUTICS TO RELEASE HALF-YEAR 2019 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON SEPTEMBER 30, 2019

Geneva, Switzerland, September 25, 2019 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, will discuss its half-year 2019...
September 24, 2019 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics Submits Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Shares

Geneva, Switzerland, 24 September 2019 -- Addex Therapeutics Ltd (SIX: ADXN) (the Company), a leading company pioneering allosteric modulation-based drug discovery and development, today announced it...
August 27, 2019 01:00 ET | Source: Addex Therapeutics

Van Leeuwenhoeck Issues Equity Research Report with Strong Buy and Price Target of CHF11-12 per Share

Geneva, Switzerland, August 27, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that the independent life...